Implication du pharmacien dans l’accompagnement des patients sous anticancéreux oraux : état des lieux dans les centres de lutte contre le cancer (CLCC)

Occhipinti, Sandrine; Petit-Jean, Emilie; Pinguet, Frédèric; Beaupin, Cécile; Daouphars, Mikaël; Parent, D.; Donamaria, C.; Bertrand, Claude; Divanon, Fabienne; Benard-Thiery, Isabelle; Chevrier, R.

doi:10.1016/j.bulcan.2017.06.012

Cited by 19 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of public health, the results of this study could be used as a model and to share experience, especially as it is a simple and transposable programme. Such an evaluation should also help to promote the securing of OAA management by structuring the city-hospital link, which is all the more important as the obstacles to the development of this type of programme are now well documented, such as the cumbersome nature of implementation, the human resources required, and the lack of funding 38…”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness of the ONCORAL multidisciplinary programme for the management of outpatients taking oral anticancer agents at risk of drug-related event: protocol for a pragmatic randomised controlled study

Huot,

Guerre,

Descotes

et al. 2024

BMJ Open

View full text Add to dashboard Cite

IntroductionThe development of oral anticancer agents (OAA) has profoundly changed cancer care, leading patients to manage their chemotherapy treatment on an outpatient basis. The prevention of iatrogenic effects of OAA remains a major concern, especially since their side effects are not less serious than those of intravenous chemotherapy. The ONCORAL programme was set up to secure the management of OAA in cancer patients followed at the Lyon University Hospital. This multidisciplinary programme involves hospital pharmacists, nurses, oncologists, and haematologists, as well as community health professionals. Given the economic stakes that this programme entails for the health system, a medico-economic study was designed.Methods and analysisThis is a prospective controlled study, with individual open-label randomisation. A total of 216 outpatients treated with OAA and at risk of developing a drug-related iatrogenic event, will be randomised (2:1) to undergo follow-up in the ONCORAL programme or usual care. The primary outcome will be the estimation of the incremental cost-effectiveness ratio (difference in total costs per quality adjusted life years gained) at 12 months between the two groups. The secondary outcomes will be evaluation of OAA management consequences (relative-dose intensity, adherence, adverse drug events, drug–drug interactions, and proven medication errors), evaluation of overall survival and cancer-related quality of life, and patient-reported outcomes in relation to the treatment. A budget impact analysis will be implemented. Patient and health professional satisfaction regarding the ONCORAL programme will be measured.Ethics and disseminationApproval to conduct this study was obtained from an Ethics Committee (Comité de Protection des Personnes Ile-de-France VI) in October 2019, and from the French data protection agency (Commission Nationale de l’Informatique et des Libertés), according to the French Law. Trial results will be disseminated at clinical conferences and published in peer-reviewed journals.Trial registrationNCT03660670.

show abstract

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness of the ONCORAL multidisciplinary programme for the management of outpatients taking oral anticancer agents at risk of drug-related event: protocol for a pragmatic randomised controlled study

Huot,

Guerre,

Descotes

et al. 2024

BMJ Open

View full text Add to dashboard Cite

show abstract

“…Communication among healthcare professionals is vital [38]; presently, no optimal support system is available [39]. Occhipinti et al showed that, although 44.4% of institutions had established city-hospital coordination, all found that this was time-consuming [40].…”

Section: Discussionmentioning

confidence: 99%

THERANOVA-LIM: Optimizing the city hospital link to support patients on oral anticancer drugs

Boucheteil,

Leobon,

Baffert

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose: Recent developments in oral chemotherapy and targeted therapies have radically changed the way in which cancer patients are managed. Ambulatory care is now common, associated with the development of organizations that foster, secure home treatments, and reinforce the city hospital link. Methods: THERANOVA-LIM (NCT04931329), a prospective, interventional study, assessed the satisfaction of healthcare professionals and patients who benefited from improved access to information on appropriate drug use imparted by a drug vigilance card or a prescription with a QR code. Results: Initially, an e-questionnaire was used to explore the practices and expectations of retail pharmacists; only 40% stated that they felt comfortable when managing patients on oral therapy. A total of 128 patients were included in the study, 55 in a “medication vigilance card” group and 73 in a “prescription with QR code” group. Patients were satisfied with the new systems and with the simplicity afforded by both the card and the prescription (p = 0.8). Similarly, 93.2% of professionals were satisfied with the new system. However, they felt that the prescription with a QR code was of greater assistance than the drug vigilance card (p = 0.02). There was no significant between-group difference in compliance (p = 0.3595) Conclusion: The two systems improved the management of patients on oral chemotherapy; the QR-coded prescription was optimal. The fact that both patients and healthcare professionals were satisfied encourages us to extend the innovations and evaluate them further. Trial Registration Number and the date of registration: ClinicalTrials.gov, NCT04931329. 2021-05-10

show abstract

“…A novel feature of our work is that we included pharmacists when co-ordinating patient management. A prospective study involving 18 French cancer centres found that only 54.5% had deployed oral anti-cancer drugs programmes that involved pharmacists, and only 44.4% featured hospital/community co-ordination [ 28 ]. Community pharmacists educate patients but also require cancer-specific education [ 29 , 30 ].…”

Section: Discussionmentioning

confidence: 99%

Prospective evaluation of an anti-cancer drugs management programme in a dedicated oral therapy center (DICTO programme)

et al. 2020

View full text Add to dashboard Cite

Oral therapies have highly modified cancer patient management and changed hospital practises. We introduce a specific Oral Therapy Centre and retrospectively review information prospectively recorded by co-ordination nurses (CNs) (the DICTO programme). We describe the roles played by CNs in the management of oral cancer therapies at Limoges Dupuytren Hospital between May 2015 and June 2018. All cancers, irrespective of stage or whether oral general chemotherapy or targeted therapy was prescribed, are included. We followed up 287 patients of median age 67 years (range 26–89 years). Of these, 76% had metastases and 44% were on first-line therapy. The vast majority (88%) of their first CN contacts occurred just after physician consultation and lasted an average of 60 min. As part of follow-up, the CNs made 2719 calls (average 10 min) to patients to educate them and to verify compliance and drug tolerance. They also received 833 calls from patients (70%) or their relatives or health professionals (30%) seeking advice on management of side effects. In addition to the initial appointments, 1069 non-scheduled follow-up visits were made to assess side effects (49.2%). The CNs devoted 5 h to each patient over 3 months of treatment (i.e. 25 min/day) and, also organised scheduled hospitalisations in the department of oncology for 51% of patients. We show the interest and real-life work in a specific oral therapy centre within oncology department with the role of CNs to facilitate the global health care of the patients. Electronic supplementary material The online version of this article (10.1007/s12032-020-01393-7) contains supplementary material, which is available to authorized users.

show abstract

Implication du pharmacien dans l’accompagnement des patients sous anticancéreux oraux : état des lieux dans les centres de lutte contre le cancer (CLCC)

Cited by 19 publications

References 16 publications

Cost-effectiveness of the ONCORAL multidisciplinary programme for the management of outpatients taking oral anticancer agents at risk of drug-related event: protocol for a pragmatic randomised controlled study

Cost-effectiveness of the ONCORAL multidisciplinary programme for the management of outpatients taking oral anticancer agents at risk of drug-related event: protocol for a pragmatic randomised controlled study

THERANOVA-LIM: Optimizing the city hospital link to support patients on oral anticancer drugs

Prospective evaluation of an anti-cancer drugs management programme in a dedicated oral therapy center (DICTO programme)

Contact Info

Product

Resources

About